{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:04:24Z","timestamp":1791993864669,"version":"4.4.0"},"reference-count":31,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Add-on biological therapy has proven to be effective in many patients with severe eosinophilic asthma. In this observational multicenter retrospective study, we report the results obtained with mepolizumab and benralizumab in severe asthmatics treated for 12 months in a real-life setting. In these patients, peripheral eosinophil levels, pulmonary function trends, exacerbation rates, systemic corticosteroid use, and symptom control were evaluated during the observation period, to understand which patients met all the criteria in order to be considered in disease remission. The percentage of remittent patients was 30.12% in the mepolizumab-treated subgroup, while in the benralizumab-treated subgroup, patients in complete disease remission were 40%, after 12 months. The results of this study confirm the efficacy of anti-IL-5 biologic drugs in the treatment of severe eosinophilic asthma in a real-life setting.<\/jats:p>","DOI":"10.3390\/ijms24032455","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T01:58:59Z","timestamp":1674784739000},"page":"2455","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Severe Asthma Remissions Induced by Biologics Targeting IL5\/IL5r: Results from a Multicenter Real-Life Study"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1874-1686","authenticated-orcid":false,"given":"Angelantonio","family":"Maglio","sequence":"first","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84100 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Vitale","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84100 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4236-7367","authenticated-orcid":false,"given":"Corrado","family":"Pelaia","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Gr\u00e6cia\u201d of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"D\u2019Amato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Federico II University, 80100 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Ciampo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84100 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Sferra","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Federico II University, 80100 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Molino","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Federico II University, 80100 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pelaia","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Gr\u00e6cia\u201d of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8265-3037","authenticated-orcid":false,"given":"Alessandro","family":"Vatrella","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84100 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"ref_1","unstructured":"(2022, December 14). GINA Main Report. Available online: https:\/\/ginasthma.org\/gina-reports\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-2600(17)30293-X","article-title":"Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990\u20132015: A systematic analysis for the Global Burden of Disease Study 2015","volume":"5","author":"Soriano","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Pelaia, C., Pelaia, G., Crimi, C., Maglio, A., Gallelli, L., Terracciano, R., and Vatrella, A. (2021). Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094369"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100441","DOI":"10.1016\/j.waojou.2020.100441","article-title":"Beliefs and preferences regarding biological treatments for severe asthma","volume":"13","author":"Bikov","year":"2020","journal-title":"World Allergy Organ. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pharmthera.2011.01.002","article-title":"Remission of asthma: The next therapeutic frontier?","volume":"130","author":"Upham","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Bafadhel","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2102583","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: What is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","article-title":"REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study","volume":"81","author":"Ribas","year":"2021","journal-title":"Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2147\/JAA.S391807","article-title":"Long-Term Efficacy and Clinical Remission After Benralizumab Treatment in Patients with Severe Eosinophilic Asthma: A Retrospective Study","volume":"ume 15","author":"Numata","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-Term Therapy Response to Anti\u2013IL-5 Biologics in Severe Asthma\u2014A Real-Life Evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12325-022-02098-1","article-title":"Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab","volume":"39","author":"Hoyte","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Maglio, A., Vitale, C., Pellegrino, S., Calabrese, C., D\u2019Amato, M., Molino, A., Pelaia, C., Triggiani, M., Pelaia, G., and Stellato, C. (2021). Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma. Biomedicines, 9.","DOI":"10.3390\/biomedicines9111550"},{"key":"ref_13","first-page":"727","article-title":"Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma","volume":"ume 15","author":"Gallardo","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-World Effectiveness and the Characteristics of a \u201cSuper-Responder\u201d to Mepolizumab in Severe Eosinophilic Asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma","volume":"159","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"key":"ref_16","unstructured":"Domingo Ribas, C., Pavord, I., Price, R.G., Howarth, P., Oppenheimer, J., Heaney, L., Nagase, H., Pizzichini, E., Banas Conejero, D., and Gardiner, F. (2022). C101. Expanding the Use of Asthma Biologics and Other Novel Therapeutics to Additional Patient Populations, American Thoracic Society. American Thoracic Society International Conference Abstracts."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2147\/JAA.S319572","article-title":"Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months","volume":"ume 14","author":"Kayser","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"A Farne, H., Wilson, A., Milan, S., Banchoff, E., Yang, F., and Powell, C.V. (2022). Anti-IL-5 therapies for asthma. Cochrane Database Syst. Rev., 2022.","DOI":"10.1002\/14651858.CD010834.pub4"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2018.09.006","article-title":"Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study","volume":"53","author":"Pelaia","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101899","DOI":"10.1016\/j.pupt.2020.101899","article-title":"Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life","volume":"61","author":"Sposato","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_21","first-page":"7461","article-title":"Severe Asthma and Long-Term Benralizumab Effectiveness in Real-Life","volume":"26","author":"Sposato","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"101966","DOI":"10.1016\/j.pupt.2020.101966","article-title":"Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma","volume":"64","author":"Menzella","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_23","first-page":"1090","article-title":"The Relationship of Asthma Biologics to Remission for Asthma","volume":"9","author":"Szefler","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pr."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Rial, M.J., and Dom\u00ednguez-Ortega, J. (2022). Inflammatory Remission in T2 Severe Asthma. Front. Allergy, 3.","DOI":"10.3389\/falgy.2022.923083"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaci.2018.08.031","article-title":"Anti\u2013IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison","volume":"143","author":"Busse","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Nagase, H., Suzukawa, M., Oishi, K., and Matsunaga, K. (2022). Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy. Allergol. Int.","DOI":"10.1016\/j.alit.2022.11.008"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1801393","DOI":"10.1183\/13993003.01393-2018","article-title":"Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: A systematic review","volume":"52","author":"Bourdin","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2147\/JAA.S340684","article-title":"Feasibility of Discontinuing Biologics in Severe Asthma: An Algorithmic Approach","volume":"ume 14","author":"Hamada","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Soendergaard, M.B., Hansen, S., Bjerrum, A.-S., Hilberg, O., Lock-Johansson, S., Haakansson, K.E.J., Ingebrigtsen, T.S., Johnsen, C.R., Rasmussen, L.M., and von B\u00fclow, A. (2022). Complete response to anti-interleukin-5 biologics in a real-life setting: Results from the nationwide Danish Severe Asthma Register. ERJ Open Res., 8.","DOI":"10.1183\/23120541.00238-2022"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kardas, G., Panek, M., Kuna, P., Damia\u0144ski, P., and Kupczyk, M. (2022). Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.983852"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1016\/j.jaip.2021.06.041","article-title":"Defining a Severe Asthma Super-Responder: Findings from a Delphi Process","volume":"9","author":"Upham","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pr."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/2455\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:16:40Z","timestamp":1760120200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/2455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24032455"],"URL":"https:\/\/doi.org\/10.3390\/ijms24032455","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]}}}